Category Archives: Healthcare

Summit Therapeutics Gets a Buy Rating from Oppenheimer

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Summit Therapeutics (NASDAQ: SMMT), with a price target of $30. The company’s shares closed on Friday at $12.20. Singh said: “We recently spent time with Summit

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin (NASDAQ: BMRN), Oxford Immunotec (NASDAQ: OXFD) and Exact Sciences (NASDAQ: EXAS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin (NASDAQ: BMRN), Oxford Immunotec (NASDAQ: OXFD) and Exact Sciences (NASDAQ: EXAS). BioMarin (NASDAQ: BMRN) In a report issued on February 22, Cory Kasimov from

BioMarin Gets a Buy Rating from Credit Suisse

In a report issued on February 23, Alethia Young from Credit Suisse maintained a Buy rating on BioMarin (NASDAQ: BMRN), with a price target of $113. The company’s shares closed on Friday at $83.05. According to TipRanks.com, Young is a

Credit Suisse Reiterates Their Buy Rating on Ascendis Pharma

Credit Suisse analyst Alethia Young reiterated a Buy rating on Ascendis Pharma (NASDAQ: ASND) on February 22 and set a price target of $50. The company’s shares closed on Friday at $61.37, close to its 52-week high of $63. According

Barclays Believes Sangamo Biosciences (NASDAQ: SGMO) Still Has Room to Grow

Barclays analyst Gena Wang maintained a Buy rating on Sangamo Biosciences (NASDAQ: SGMO) on February 22 and set a price target of $30. The company’s shares closed on Friday at $24.95, close to its 52-week high of $27.50. According to

Ultragenyx Gets a Buy Rating from Robert W. Baird

In a report issued on February 20, Michael Ulz from Robert W. Baird reiterated a Buy rating on Ultragenyx (NASDAQ: RARE), with a price target of $70. The company’s shares closed yesterday at $47.86, close to its 52-week low of